Skip to main content

Table 3 Multivariate analysis for OHA classes pre and post CDA 2008 guidelines

From: Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines

 

No (%) of patients or mean ± SD

Multivariate analysis*

 

Pre

Post

OR (95% CI)

p value

n = 670

n = 609

Classes of OHA†

    

• Metformin ± other‡

601 (89.7)

576 (94.6)

1.00 [Reference]

 

• TZD

18 (2.7)

3 (0.5)

0.21 (0.08-0.55)

0.001

• Sulfonylurea

54 (8.1)

27 (4.4)

0.68 (0.43-1.09)

0.11

• Other‡

3 (0.5)

4 (0.7)

1.44 (0.29-7.06)

0.65

  1. Note: OHA Oral hypoglycemic agent, TZD Thiazolidinediones, CDA Canadian Diabetes Association.
  2. *Multivariate analysis done for patients’ gender, age and co-morbidities, guidelines, MD evidence scale, gender, practice experience and drugs.
  3. †Patients initiated on more than 1 drug (with no Metformin) were counted in both classes.
  4. ‡Includes Alpha-1 glucosidase inhibitor (Acarbose), DPP-4 inhibitor (Sitagliptin) and Meglitinides.
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us